These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29468424)

  • 1. Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography.
    Presnell AL; Chuchuen O; Simons MG; Maher JR; Katz DF
    Drug Deliv Transl Res; 2018 Jun; 8(3):843-852. PubMed ID: 29468424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography.
    Chuchuen O; Maher JR; Henderson MH; Desoto M; Rohan LC; Wax A; Katz DF
    PLoS One; 2017; 12(9):e0185633. PubMed ID: 28961280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy.
    Chuchuen O; Henderson MH; Sykes C; Kim MS; Kashuba AD; Katz DF
    PLoS One; 2013; 8(12):e85124. PubMed ID: 24386455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
    Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
    PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
    Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.
    Gao Y; Katz DF
    PLoS One; 2017; 12(1):e0167696. PubMed ID: 28114388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
    Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
    J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
    Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Label-Free Measurements of Tenofovir Diffusion Coefficients in a Microbicide Gel Using Raman Spectroscopy.
    Chuchuen O; Maher JR; Simons MG; Peters JJ; Wax AP; Katz DF
    J Pharm Sci; 2017 Feb; 106(2):639-644. PubMed ID: 27837968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.
    Pereira LE; Singletary T; Martin A; Dinh CT; Deyounks F; Holder A; McNicholl J; Buckheit KW; Buckheit RW; Ham A; Katz DF; Smith JM
    Drug Deliv Transl Res; 2018 Oct; 8(5):1180-1190. PubMed ID: 29761350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.
    Romas L; Birse K; Mayer KH; Abou M; Westmacott G; Giguere R; Febo I; Cranston RD; Carballo-Diéguez A; McGowan I; Burgener A
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1005-1015. PubMed ID: 27316778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
    Hiruy H; Fuchs EJ; Marzinke MA; Bakshi RP; Breakey JC; Aung WS; Manohar M; Yue C; Caffo BS; Du Y; Abebe KZ; Spiegel HM; Rohan LC; McGowan I; Hendrix CW
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1098-108. PubMed ID: 26227279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
    Bakshi RP; Breakey J; Manohar M; Jois B; Fuchs EJ; Marzinke MA
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):354-356. PubMed ID: 29258331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
    Richardson-Harman N; Hendrix CW; Bumpus NN; Mauck C; Cranston RD; Yang K; Elliott J; Tanner K; McGowan I; Kashuba A; Anton PA
    PLoS One; 2014; 9(10):e111507. PubMed ID: 25350130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
    PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
    Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
    Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
    McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
    PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
    PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery.
    Jarrett AM; Gao Y; Hussaini MY; Cogan NG; Katz DF
    J Pharm Sci; 2016 May; 105(5):1772-1778. PubMed ID: 27012224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.